Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Radhoud University Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bavarian Nordic Reports New Preclinical Data for COVID-19 Vaccine Confirming Potential for Broad Protection against SARS-CoV2 Variants","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Bavarian Nordic","sponsor":"Danish Ministry of Health","pharmaFlowCategory":"D","amount":"$124.4 million","upfrontCash":"$12.4 million","newsHeadline":"Bavarian Nordic\u2019s COVID-19 Funding Agreement with the Danish Ministry of Health Receives Final Approval from Parliament","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Bavarian Nordic"},{"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"company":"Union Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Union Therapeutics A\/s Completes Dosing of Healthy Volunteers with UNI911 (inhaled Niclosamide) for Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Union Therapeutics"},{"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"SNIPR Biome"},{"company":"SNIPR Biome","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"DENMARK","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"SNIPR Biome"}]

SNIPR Biome

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage

Details:

SNIPR001, a CRISPR-armed bacteriophage cocktail that targets the prevention of antibiotic-resistant E. coli infections in hematological cancer patients.

Lead Product(s): SNIPR001

Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 02, 2022

ASK
US

Upload
your Pipeline Activity

SNIPR Biome

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001

Details:

The experimental CRISPR therapeutic, SNIPR001, is designed to selectively target and eradicate E. coli in the gut, thus preventing translocation of these bacteria to the bloodstream, in a high-risk population of hematological cancer patients at risk for neutropenia.

Lead Product(s): SNIPR001

Therapeutic Area: Infections and Infectious Diseases Product Name: SNIPR001

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 20, 2022

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic’s COVID-19 Funding Agreement with the Danish Ministry of Health Receives Final Approval from Parliament

Details:

The funding agreement approved on the basis of results shown by ABNCoV2 in preclinical models inducing durable and highly protective response from a COVID-19 challenge and the proceeds will advance the development of ABNCoV2.

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: cVLP-RBD

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Danish Ministry of Health

Deal Size: $124.4 million Upfront Cash: $12.4 million

Deal Type: Funding September 24, 2021

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Reports New Preclinical Data for COVID-19 Vaccine Confirming Potential for Broad Protection against SARS-CoV2 Variants

Details:

A neutralization test of samples from the study of ABNCoV2 has now confirmed similarly high levels of neutralizing antibodies against the SARS-CoV2 variants B.1.1.7 (British) and B.1.351 (South African).

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 29, 2021

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial

Details:

The latest data confirm the previous strong immunogenicity results already published, and further demonstrate a protective efficacy of ABNCoV2 post-challenge with SARS-CoV-2.

Lead Product(s): ABNCoV2

Therapeutic Area: Infections and Infectious Diseases Product Name: ABNCoV2

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Radhoud University Medical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 08, 2021

ASK
US

Upload
your Pipeline Activity

Union Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Union Therapeutics A/s Completes Dosing of Healthy Volunteers with UNI911 (inhaled Niclosamide) for Covid-19

Details:

UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911. UNI911 utilizes an optimized salt form of niclosamide, an existing potent inhibitor of SARS-Cov-2 by Institut Pasteur Korea.

Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 25, 2020

ASK
US

Upload
your Pipeline Activity

Union Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

UNION Receives Approval From Danish Medicines Agency to Initiate Clinical Study With Niclosamide for Treatment of COVID-19

Details:

Danish Medicines Agency has approved initiation of a clinical study with an optimized salt form of niclosamide as a new treatment candidate for COVID-19.

Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases Product Name: UNI911

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

ASK
US

Upload
your Pipeline Activity

Bavarian Nordic

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bavarian Nordic Announces Topline Results from Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine

Details:

Data from the study showed that the vaccine was well tolerated and immunogenic across all dose groups.

Lead Product(s): MVA-BN-WEV

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 08, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY